Bolt Revenue Jumps 39 Percent in Q2
Bolt Biotherapeutics (NASDAQ:BOLT), a clinical-stage biotechnology company focused on next-generation cancer immunotherapies, posted second quarter 2025 results on August 14, 2025. The standout news was a significant improvement in GAAP earnings and operating loss, helped by cost reductions after a major restructuring. Revenue (GAAP) was $1.80 million, beating the analyst consensus of $0.82 million (GAAP), while loss per share (GAAP) was $(4.46), markedly better than the GAAP estimate of $(6.30). Management highlighted stabilized operations and an improved financial position as it moves forward with its pipeline programs. The quarter showed progress in tightening expenses and early clinical milestones. Still, Bolt's outlook remains closely tied to the success of its lead drug candidates and securing new strategic partnerships.
Source: Analyst estimates for the quarter provided by FactSet.
Bolt Biotherapeutics is advancing a new class of immuno-oncology medicines called immune-stimulating antibody conjugates, known as ISACs. These drugs are designed to activate the body's own immune cells to recognize and attack cancer. The company also works on macrophage agonist antibodies, which aim to turn a type of immune cell against tumors.
Source Fool.com
